"What are beta blockers and how do they work?
Beta blockers, also known as beta-adrenergic blocking agents, are a class of drugs that works by blocking the neurotransmitters norepinephrine and epinephrine from binding to receptors. "...
COREG (carvedilol) is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see DRUG INTERACTIONS and Clinical Studies].
Left Ventricular Dysfunction Following Myocardial Infarction
COREG (carvedilol) is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of 40% (with or without symptomatic heart failure) [see Clinical Studies].
COREG (carvedilol) is indicated for the management of essential hypertension [see Clinical Studies]. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see DRUG INTERACTIONS].
DOSAGE AND ADMINISTRATION
COREG (carvedilol) should be taken with food to slow the rate of absorption and reduce the incidence of orthostatic effects.
DOSAGE MUST BE INDIVIDUALIZED AND CLOSELY MONITORED BY A PHYSICIAN DURING UP-TITRATION. Prior to initiation of COREG (carvedilol) , it is recommended that fluid retention be minimized. The recommended starting dose of COREG (carvedilol) is 3.125 mg twice daily for 2 weeks. If tolerated, patients may have their dose increased to 6.25, 12.5, and 25 mg twice daily over successive intervals of at least 2 weeks. Patients should be maintained on lower doses if higher doses are not tolerated. A maximum dose of 50 mg twice daily has been administered to patients with mild-to-moderate heart failure weighing over 85 kg (187 lbs).
Patients should be advised that initiation of treatment and (to a lesser extent) dosage increases may be associated with transient symptoms of dizziness or lightheadedness (and rarely syncope) within the first hour after dosing. During these periods, patients should avoid situations such as driving or hazardous tasks, where symptoms could result in injury. Vasodilatory symptoms often do not require treatment, but it may be useful to separate the time of dosing of COREG (carvedilol) from that of the ACE inhibitor or to reduce temporarily the dose of the ACE inhibitor. The dose of COREG (carvedilol) should not be increased until symptoms of worsening heart failure or vasodilation have been stabilized.
Fluid retention (with or without transient worsening heart failure symptoms) should be treated by an increase in the dose of diuretics.
The dose of COREG (carvedilol) should be reduced if patients experience bradycardia (heart rate < 55 beats/minute).
Episodes of dizziness or fluid retention during initiation of COREG (carvedilol) can generally be managed without discontinuation of treatment and do not preclude subsequent successful titration of, or a favorable response to, carvedilol.
Left Ventricular Dysfunction Following Myocardial Infarction
DOSAGE MUST BE INDIVIDUALIZED AND MONITORED DURING UP-TITRATION. Treatment with COREG (carvedilol) may be started as an inpatient or outpatient and should be started after the patient is hemodynamically stable and fluid retention has been minimized. It is recommended that COREG (carvedilol) be started at 6.25 mg twice daily and increased after 3 to 10 days, based on tolerability, to 12.5 mg twice daily, then again to the target dose of 25 mg twice daily. A lower starting dose may be used (3.125 mg twice daily) and/or the rate of up-titration may be slowed if clinically indicated (e.g., due to low blood pressure or heart rate, or fluid retention). Patients should be maintained on lower doses if higher doses are not tolerated. The recommended dosing regimen need not be altered in patients who received treatment with an IV or oral β-blocker during the acute phase of the myocardial infarction.
DOSAGE MUST BE INDIVIDUALIZED. The recommended starting dose of COREG (carvedilol) is 6.25 mg twice daily. If this dose is tolerated, using standing systolic pressure measured about 1 hour after dosing as a guide, the dose should be maintained for 7 to 14 days, and then increased to 12.5 mg twice daily if needed, based on trough blood pressure, again using standing systolic pressure one hour after dosing as a guide for tolerance. This dose should also be maintained for 7 to 14 days and can then be adjusted upward to 25 mg twice daily if tolerated and needed. The full antihypertensive effect of COREG (carvedilol) is seen within 7 to 14 days. Total daily dose should not exceed 50 mg.
Concomitant administration with a diuretic can be expected to produce additive effects and exaggerate the orthostatic component of carvedilol action.
COREG (carvedilol) should not be given to patients with severe hepatic impairment [see CONTRAINDICATIONS].
Dosage Forms And Strengths
The white, oval, film-coated tablets are available in the following strengths: 3.125 mg– engraved with 39 and SB, 6.25 mg–engraved with 4140 and SB, 12.5 mg–engraved with 4141 and SB, and 25 mg–engraved with 4142 and SB.
Storage And Handling
The white, oval, film-coated tablets are available in the following strengths: 3.125 mg– engraved with 39 and SB, in bottles of 100; 6.25 mg–engraved with 4140 and SB, in bottles of 100; 12.5 mg–engraved with 4141 and SB, in bottles of 100; 25 mg–engraved with 4142 and SB, in bottles of 100. The 6.25 mg, 12.5 mg, and 25 mg tablets are TILTAB tablets.
- 3.125 mg 100's: NDC 0007-4139-20
- 6.25 mg 100's: NDC 0007-4140-20
- 12.5 mg 100's: NDC 0007-4141-20
- 25 mg 100's: NDC 0007-4142-20
Store below 30°C (86°F). Protect from moisture. Dispense in a tight, light-resistant container.
Manufactured for : GlaxoSmithKline, Research Triangle Park, NC 27709. Manufactured by: Patheon Puerto Rico, Inc., Manati, PR 00674 USA
Last reviewed on RxList: 2/25/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Coreg Information
Coreg - User Reviews
Coreg User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on handling your hypertension.